Analyst Reports
-
28 Sep 2023
Edison Insight: September 2023
Analyst: Pooya Hemami
Actinogen Medical Investment Summary and Industry Outlook. Prices at 24 Apr 2023This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.
Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.
Continue to report -
08 Jun 2023
Edison Investment Research update
Refining the upcoming XanaMIA Phase 2b studyAnalyst: Pooya Hemami
This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.
Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.
Continue to report -
02 May 2023
Edison Investment Research Quarterly update
Continued focus on XanamemAnalysts: Pooya Hemami
This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.
Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.
Continue to report -
27 Apr 2023
Edison Insight: April 2023
Analyst: Pooya Hemami
Actinogen Medical Investment Summary and Industry Outlook. Prices at 24 Apr 2023This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.
Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.
Continue to report -
30 Mar 2023
Edison Healthcare Insight: March 2023
Analyst: Pooya Hemami
Actinogen Medical Investment Summary and Industry Outlook. Prices at 27 Mar 2023This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.
Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.
Continue to report -
15 Mar 2023
Edison Investment Research H123 update
Getting ready for the next Alzheimer’s studyAnalysts: Pooya Hemami
This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.
Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.
Continue to report -
09 Feb 2023
Edison Healthcare Insight: February 2023
Analyst: Pooya Hemami
Refer to page 5 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 6 Feb 2023This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.
Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.
Continue to report -
12 Jan 2023
Spark Plus Research Note
Actinogen – A company to never forgetAnalyst: Cyprus Sia
This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Spark Plus Pte Ltd. The report solely reflects the views of Spark Plus Pte Ltd.
Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Spark Plus Pte Ltd at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.
Continue to report -
06 Jan 2023
Edison themes: Outlook for 2023
Biotechs remain central to novel drug developmentAnalyst: Soo Romanoff and Dr Adam McCarter
This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.
Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.
Continue to report
2024 Annual General Meeting
Actinogen’s next Annual General Meeting
Date: 14 November 2024
Read more